Kodet R, Newton W A, Hamoudi A B, Asmar L, Wharam M D, Maurer H M
Department of Pathology, 2nd Faculty of Medicine, Prague, Czech Republic.
Med Pediatr Oncol. 1997 Jul;29(1):51-60. doi: 10.1002/(sici)1096-911x(199707)29:1<51::aid-mpo10>3.0.co;2-7.
Children and adolescents who develop rhabdomyosarcoma (RMS) and related sarcomas in the orbit and treated on Intergroup Rhabdomyosarcoma protocols have had an extremely high cure rate. This study evaluates the possible relationship between their tumor morphologic subtypes and this high cure rate. The histology of tumors was re-reviewed from 229 of the 264 patients with tumors of the orbit, conjunctiva, and eyelids treated on Intergroup Rhabdomyosarcoma Studies (IRS I, II, III, and IV pilot protocols, and followed through July, 1992. Immunohistochemistry was applied in selected cases. Clinical correlations were done on all 264 cases including both the re-reviewed cases and those reviewed only by the IRS Pathology committee. The 5-year survival rate of 24 children with alveolar RMS was 74% (p < .001). All five infants diagnosed to have an alveolar RMS died before the age of one. Two hundred and twenty-one patients (84%) had embryonal RMS. About three-fourths of the re-reviewed embryonal RMS tumors showed only minimal rhabdomyoblastic differentiation. Thirty-one had a spindle cell RMS, two were anaplastic variants. The 5-year survival rate for patients with embryonal RMS subtypes combined was 94%, and 97% for the 144 patients with poorly differentiated embryonal RMS. In contrast, 90 of 432 IRS II patients treated for poorly differentiated embryonal RMS located in extraocular sites had a 66% survival estimate.
在眼眶部患横纹肌肉瘤(RMS)及相关肉瘤并按照横纹肌肉瘤协作组方案接受治疗的儿童和青少年,其治愈率极高。本研究评估了他们肿瘤形态学亚型与这种高治愈率之间可能存在的关系。对横纹肌肉瘤协作组研究(IRS I、II、III和IV试点方案)中接受治疗的264例眼眶、结膜和眼睑肿瘤患者中的229例肿瘤组织学进行了重新审查,并随访至1992年7月。对部分病例应用了免疫组织化学方法。对所有264例病例进行了临床相关性分析,包括重新审查的病例和仅由IRS病理委员会审查的病例。24例肺泡型RMS患儿的5年生存率为74%(p <.001)。所有诊断为肺泡型RMS的5例婴儿均在1岁前死亡。221例患者(84%)患有胚胎型RMS。重新审查的胚胎型RMS肿瘤中约四分之三仅显示极少的横纹肌母细胞分化。31例为梭形细胞RMS,2例为间变性变体。胚胎型RMS各亚型患者的5年生存率合并为94%,144例低分化胚胎型RMS患者的5年生存率为97%。相比之下,432例接受治疗的位于眼外部位的低分化胚胎型RMS的IRS II患者中,90例的生存估计率为66%。